Sinclair Jonathan, Du XuanYi, Shadwell Gareth, Dillon Stephanie, Butters Bobbie, Bottoms Lindsay
Research Centre for Applied Sport, Physical Activity and Performance, School of Health, Social Work & Sport, University of Central Lancashire, Lancashire, United Kingdom.
School of Medicine & Dentistry, University of Central Lancashire, Lancashire, United Kingdom.
PLoS One. 2025 May 7;20(5):e0321986. doi: 10.1371/journal.pone.0321986. eCollection 2025.
Hypertension is the predominant risk factor for cardiovascular disease morbidity and mortality, with significant healthcare utilization and expenditure. Pharmaceutical management is habitually adopted; although its long-term effectiveness remains ambiguous, and accompanying adverse effects are disquieting. Peppermint owing to its abundance of menthol and flavonoids, possesses a range of potential hypertensive benefits.
Our previous trial has shown that peppermint is able to mediate significant improvements in systolic blood pressure in healthy individuals. But there has yet to be any randomized placebo-controlled studies, examining the efficacy of peppermint supplementation in hypertensive individuals.
This study proposes a placebo randomized controlled trial, exploring the effects of daily peppermint oil supplementation on outcomes pertinent to hypertensive disease in individuals with pre and stage 1 hypertension.
This 20-day, parallel randomized, placebo-controlled trial will recruit 40 individuals, assigned to receive either 100μL per day of either Peppermint oil or a peppermint flavoured placebo. The primary trial outcome will be the between-group difference in systolic blood pressure from baseline to post-intervention. Secondary outcome measurements will be between-group differences in anthropometric, haematological, diastolic blood pressure/ resting heart rate, psychological wellbeing, and sleep efficacy indices. Statistical analysis will be conducted on an intention-to-treat basis using linear mixed effects models to contrast differences in the changes from baseline to 20-days between the two trial arms.
Ethical approval has been granted by the University of Central Lancashire (HEALTH 01074) and the study has formally been registered as a trial (NCT05561543). Dissemination of the trial findings will be through publication in a peer-reviewed journal.
ClinicalTrials.gov NCT05561543.
HEALTH 01074.
高血压是心血管疾病发病和死亡的主要危险因素,会导致大量医疗资源的使用和支出。药物治疗是常用方法;尽管其长期疗效尚不明确,且伴随的不良反应令人担忧。薄荷富含薄荷醇和黄酮类化合物,具有一系列潜在的降血压益处。
我们之前的试验表明,薄荷能够使健康个体的收缩压显著改善。但尚未有任何随机安慰剂对照研究,探讨补充薄荷对高血压患者的疗效。
本研究提出一项安慰剂随机对照试验,探讨每日补充薄荷油对高血压前期和1期高血压患者与高血压疾病相关结局的影响。
这项为期20天的平行随机安慰剂对照试验将招募40名个体,分为两组,分别每天接受100μL薄荷油或薄荷味安慰剂。主要试验结局将是干预前后两组收缩压的组间差异。次要结局指标将是两组在人体测量、血液学、舒张压/静息心率、心理健康和睡眠功效指数方面的组间差异。将采用线性混合效应模型,在意向性分析的基础上进行统计分析,以对比两个试验组从基线到20天变化的差异。
中央兰开夏大学已批准伦理许可(HEALTH 01074),该研究已正式注册为一项试验(NCT05561543)。试验结果将通过在同行评审期刊上发表进行传播。
ClinicalTrials.gov NCT05561543。
HEALTH 01074。